Eli Lilly (LLY.US) initiates Phase III clinical trial for FR ADC.

On October 9, the global clinical trial registry website showed that Eli Lilly (LLY.US) has initiated the first Phase III clinical trial (FRAmework-01) for the FR ADC drug LY4170156. LY4170156 is an FR ADC drug developed by Mablink Bioscience (acquired by Eli Lilly), with a payload of the topoisomerase I inhibitor irinotecan and a DAR value of 8. According to data from the PharmaCube NextPharma database, there are currently 27 FR ADC drugs in development globally, with 11 in clinical stages. Apart from the already marketed trastuzumab emtansine, Rinatabart sesutecan (Genmab), BAT8006 (Bio-Thera Solutions), and LY4170156 are the 3 fastest advancing drugs, all of which have initiated Phase III clinical trials.